Mylan Launches Hulio (adalimumab, biosimilar) in EU for Autoimmune Diseases

Mylan Launches Hulio (adalimumab, biosimilar) in EU for Autoimmune Diseases

Shots:

  • AbbVie’s Humira biosimilar, Hulio received EU approval in Sep 2018, reviewing CHMP approval which included biosimilarity data regarding analytical, functional, clinical and immunogenicity of Hulio with Humira
  • The launch of Hulio post EU approval is available in all 28 EU member countries including Norway, Iceland and Liechtenstein. In July, 2018 Humira had brand sales of ~$4.3B in EU
  • Adalimumab IV is a TNFi indicated for treatment of autoimmune diseases. In H1’18, Mylan and Kyowa Kirin entered into a collaboration for Hulio’s commercialization in EU

Click here to read full press release/ article | Ref: Mylan| Image: Investor Business Daily